Effects of the mineralocorticoid fludrocortisone on fibrinolytic function in healthy subjects

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 1, Issue 4, 2000, Pages 357-360

  Lottermoser, Katja ^a   Hertfelder, Hans Jörg ^b   Wehling, Martin ^c   Schiermeyer, Beate ^a   Vetter, Hans ^a   Düsing, Rainer ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Institut für Experimentelle Hämatologie und Transfusionsmedizin   (Germany)

^c Fak Klin Medizin Mannheim   (Germany)

Author keywords

Angiotensin II; Fibrinoiysis; Fludrocortisone; Mineralocorticoid; Plasma renin activity; Plasminogen activator inhibitor 1; Tissue plasminogen activator

Indexed keywords

FLUDROCORTISONE; MINERALOCORTICOID; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD; CIRCADIAN RHYTHM; DRUG EFFECT; FIBRINOLYSIS; HUMAN; MALE; PILOT STUDY; REFERENCE VALUE;

ADULT; CIRCADIAN RHYTHM; FIBRINOLYSIS; FLUDROCORTISONE; HUMANS; MALE; MINERALOCORTICOIDS; PILOT PROJECTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; REFERENCE VALUES; RENIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0034585814     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2000.066     Document Type: Article

References (35)

1. Brunner HR, Laragh JH, Baer L et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972;286:441-9.
2. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH.Association of renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Meet 1991;324:1098-104.
3. Lottermoser K, Vetter H, Düsing R. Blood pressure-independent atherogenic and thromboembolic mechanisms of the renin-angiotensin-aldosterone system. J Clin Basic Cardiol (in press).
4. Gray RP, Yudkins JS, Patterson DL. Plasminogen activator inhibitor: a risk factor of myocardial infarction in diabetic patients. Br Heart J 1993;69:228-32.
5. Scarabin PY, Aillaud MF, Amouyel P et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction-the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost 1998;80:749-56.
6. Thogersen AM, Jansson JH, Boman K et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:22-41-7.
7. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995;95:995-1001.
8. Nishimura H, Tsuji H, Masuda H et al. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue-type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 1997;77;1189-95.
9. Hamdan AD, Quist WC, Gagne JB et al. Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation 1996;93:1073-8.
10. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993;87:1969-73.
11. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998;32:965-71.
12. Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999;34:285-90.
13. Pedersen OD, Gram J, Bagger H, Keller N, Jespersen J. Regulation of tissue-type plasminogen activator-mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischemic heart disease: possible unfavourable effect of diuretics. Coronary Artery Disease 1994;5:617-23.
14. Lottermoser K, Weisser B, Hertfelder H-J, Wöstmann B, Vetter H, Düsing R. Antihypertensive drug treatment and fibrinolytic function. AJH 1998;11:378-84.
15. Goodfield NE, Newby DE, Ludlam CA, Flapan AD. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin-converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999;99:2983-5.
16. Pitt B, Zannad F, Remme WJ et al. for the RALES Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
17. Brilla CG, Maisch B. Regulation of the structural remodeling of the myocardium: from hypertrophy to heart failure. Europ Heart J 1994;15(Suppl D):45-52.
18. Brilla CG, Maisch B, Zhou G, Weber KT. Hormonal regulation of cardiac fibroblast function. Eur Heart J 1995;16(Suppl C):45-50.
19. Brown NJ, Kim KS, Chen YQ et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000;85(1):336-44.
20. Verheijen JH, Chang GTG, Kluft C. Evidence for the occurence of a fast acting inhibitor of tissue-type plasminogen activator in plasma. Thromb Haemost 1984;51:392-495.
21. Haber E, KoernerT, Page LB et al. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol 1969;29:1349-55.
22. Lottermoser K, Hertfelder H-J, Vetter H, Düsing R. Fibrinolytic function in diuretic-induced volumen depletion. Am J Hypertens 13:359-63.
23. Nakamura S, Nakamura I, Nishimura H, Vaughan D, Fogo A. Plasminogen activator inhibitor-1 (PAI-1) is induced directly by angiotensin type 1 receptor in vivo. J Am Soc Nephrol 1998;9:523 A.
24. Erdem Y, Usalan C, Haznedaroglu IC et al. Effects of angiotensin-converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999;12:1071-6.
25. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995;95:995-1001.
26. Kerins DM, Hao Q, Vauglian DE. Angiotensin induction of PAI-expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995;96:2515-520.
27. Daley WL, Flavin S, Vaughan DE. The induction of plasminogen activator inhibitor-1 by the hexapeptide (3-8) fragment of the renin angiotensin system is not pressor dependent. Circulation 1998;98 (Suppl.):I 519.
28. Verrey F. Early aldosterone action: toward filling the gap between transcription and transport. Am J Physiol 1999;277(3Pt2):F319-327.
29. Stewart PM. Mineralocorticoid hypertension. Lancet 1999;353:1341-7.
30. Funder JW. Aldosterone, salt and cardiac fibrosis. Clin Exp Hypertens 1997;19:885-99.
31. Wehling M. Specific, nongenomic steroid action. Ann Rev Physiol 1997;59:365-93.
32. Christ M, Wehling M. Cardiovascular steroid actions: swift swallows or sluggish snails? Cardiovasc Res 1998;40:34-44.
33. Hollenberg NK, Chenitz WR, Adams DF, Williams GH. Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man. J Clin Invest 1974;54:34-42.
34. Oelkers W, Brown JJ, Fraser R, Leber AF, Morton JJ, Robertson JI. Sensitization of the adrenal cortex to angiotensin II in sodium-deplete man. Circ Res 1974;40:69-77.
35. Ullian ME, Fine JJ. Mechanisms of enhanced angiotensin II-stimulated signal transduction in vascular smooth muscle by aldosterone. J Cell Physiol 1994;161(2):201-8.